Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that Peter Greenleaf has been appointed to the Company's Board of Directors, effective immediately.
Mr. Greenleaf brings to Mast Therapeutics' Board of Directors over 20 years of experience in the biopharmaceutical industry, including a track record of effective leadership through periods of significant growth and extensive global commercial operations, strategic planning, and product development expertise.